Integrating network pharmacology and experimental validation reveals PI3K/AKT as a critical pathway in pachymic acid-induced inhibition of hepatocellular carcinoma
By: Jun Liang, Hongyu Zhang, Shixin Pan, Tao Si, Minzhong Tang and Zheng Peng
Authors
Jun Liang
Department of Clinical Laboratory, Liuzhou Traditional Chinese Medical Hospital, Liuzhou, Guangxi, China
School of Clinical Medical College, Guilin Medical University, Guilin, Guangxi, China
Department of Scientific Research, Wuzhou Red Cross Hospital, Wuzhou, Guangxi, China
Hongyu Zhang
Department of Clinical Laboratory, Liuzhou Traditional Chinese Medical Hospital, Liuzhou, Guangxi, China
Shixin Pan
Department of Scientific Research, Wuzhou Red Cross Hospital, Wuzhou, Guangxi, China
Tao Si
Department of Oncology, Liuzhou Traditional Chinese Medical Hospital, Liuzhou, Guangxi, China
Minzhong Tang
School of Clinical Medical College, Guilin Medical University, Guilin, Guangxi, China
Department of Scientific Research, Wuzhou Red Cross Hospital, Wuzhou, Guangxi, China
Zheng Peng
Department of Clinical Laboratory, Liuzhou Traditional Chinese Medical Hospital, Liuzhou, Guangxi, China
Postdoctoral Research Workstation, Wuzhou Red Cross Hospital, Wuzhou, Guangxi, China
Language: English
Accepted on: Oct 11, 2026
Published on: Oct 26, 2026
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2026 Jun Liang, Hongyu Zhang, Shixin Pan, Tao Si, Minzhong Tang, Zheng Peng, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.